Under the agreement, Rallybio will also receive low single-digit royalties on future net sales and may be eligible for additional payments if Recursion sells the program.

The program originated from a joint venture between the two companies that combined Rallybio’s expertise in HPP research with Recursion’s AI platform. Under the agreement, Rallybio will also receive ...

AI enabled Design and Development The program originated from a joint venture with Rallybio, with Recursion leading the precision design of REV102.

Some new investors pitched in to Recursion Pharmaceuticals Inc.'s $121 million series C financing, adding to the industry's vision of the importance of AI and machine learning.

Recursion announces the close of a $121 million Series C financing to advance its machine learning-enabled approach to drug discovery and development.

By securing full ownership, Recursion Pharmaceuticals can now independently advance the program, aiming to deliver the first oral, disease-modifying treatment for HPP. Under the deal, RXRX will ...

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...

The REV102 program originated from a joint venture between Rallybio and Recursion focused on the discovery and development of novel, orally available small molecule inhibitors of ENPP1 for the ...

The REV102 program originated from a joint venture between Rallybio and Recursion focused on the discovery and development of novel, orally available small molecule inhibitors of ENPP1 for the ...

If that's true, good luck debugging a program that you've written depending on that optimization to not overflow your stack. I've been trying to avoid recursion in C# for stack-overflow fears.